Cytopenia Clinical Trials

170 recruitingLast updated: June 18, 2026

There are 170 actively recruiting cytopenia clinical trials across 49 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1, Phase 4. Top locations include Tianjin, Tianjin Municipality, China, Beijing, Beijing Municipality, China, Tianjin, China. Updated daily from ClinicalTrials.gov.


Cytopenia Trials at a Glance

170 actively recruiting trials for cytopenia are listed on ClinicalTrialsFinder across 6 cities in 49 countries. The largest study group is Phase 2 with 78 trials, with the heaviest enrollment activity in Tianjin, Beijing, and Tianjin. Lead sponsors running cytopenia studies include Institute of Hematology & Blood Diseases Hospital, China, Peking University People's Hospital, and Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Treatments under study

About Cytopenia Clinical Trials

Looking for clinical trials for Cytopenia? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cytopenia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cytopenia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 170 trials

Recruiting
Phase 2Phase 3

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

Immune Thrombocytopenic PurpuraITPIdiopathic Thrombocytopenic Purpura+4 more
argenx24 enrolled10 locationsNCT07194850
Recruiting
Phase 2

Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Idiopathic CD4-PositiveT-Lymphocytopenia
National Institute of Allergy and Infectious Diseases (NIAID)40 enrolled1 locationNCT02015013
Recruiting
Phase 2

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)Primary Evans Syndrome (ES)
Novartis Pharmaceuticals164 enrolled2 locationsNCT07421167
Recruiting
Phase 1

RN1201 Injection in the Treatment of Antibody-Mediated Diseases

Refractory Immune-mediated Platelet Transfusion RefractorinessRelapsed or Refractory Immune Thrombocytopenia
The First Affiliated Hospital of Soochow University9 enrolled1 locationNCT07072247
Recruiting

Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

Baseline Thrombocytopenia
Methodist Health System300 enrolled1 locationNCT06223607
Recruiting

CHIP/CCUS Natural History Protocol

Clonal Cytopenia of Undetermined SignificanceClonal Hematopoiesis of Indeterminate Potential
National Heart, Lung, and Blood Institute (NHLBI)306 enrolled1 locationNCT04102423
Recruiting

Investigation of the Genetics of Hematologic Diseases

Diamond-Blackfan AnemiaDyskeratosis CongenitaFanconi Anemia+10 more
St. Jude Children's Research Hospital1,716 enrolled1 locationNCT02720679
Recruiting

Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia

Cryptococcal MeningitisWartsIdiopathic CD4+ Lymphocytopenia
National Institute of Allergy and Infectious Diseases (NIAID)950 enrolled1 locationNCT00867269
Recruiting
Phase 3

A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Thrombocytopenia, Neonatal Alloimmune
Janssen Research & Development, LLC39 enrolled21 locationsNCT06449651
Recruiting
Phase 3

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Thrombocytopenia, Neonatal Alloimmune
Janssen Research & Development, LLC50 enrolled26 locationsNCT06533098
Recruiting
Phase 2

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

Warm Autoimmune Hemolytic AnemiaPrimary immune thrombocytopenia
Novartis Pharmaceuticals60 enrolled22 locationsNCT07039422
Recruiting
Phase 2

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Severe Aplastic AnemiaAcquired Amegakaryocytic ThrombocytopeniaAcquired Pure Red Cell Aplasia+1 more
Masonic Cancer Center, University of Minnesota60 enrolled1 locationNCT06412497
Recruiting
Phase 2

Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)

Myelodysplastic SyndromeClonal Cytopenia of Undetermined Significance
University of Colorado, Denver10 enrolled1 locationNCT07579429
Recruiting
Phase 2

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Immune Thrombocytopenia
Incyte Corporation56 enrolled40 locationsNCT07104565
Recruiting
Not Applicable

Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis

ThrombocytopeniaImmune ThrombocytopeniaMyelodysplasia
University Hospital, Bordeaux225 enrolled1 locationNCT04800458
Recruiting

Prediction of Platelet Function Using Viscoelastic Test (ROTEM® Sigma) in Obstetric Anesthesia.

ThrombocytopeniaPostpartum Haemorrhage (PPH)
Nicolas Brogly85 enrolled1 locationNCT07616349
Recruiting
Phase 2

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

Immune Thrombocytopenia (ITP)
Nuvig Therapeutics, Inc.30 enrolled1 locationNCT07095127
Recruiting
Phase 1

Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia

Immune Thrombocytopenia
Guangdong Hengrui Pharmaceutical Co., Ltd10 enrolled1 locationNCT07206758
Recruiting
Phase 1

IASO-782 in Autoimmune Hematological Diseases

Autoimmune ThrombocytopeniaWarm Autoimmune Haemolytic Anaemia
Shanghai IASO Biotechnology Co., Ltd16 enrolled2 locationsNCT06534021
Recruiting
Phase 3

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

Immune Thrombocytopenia
Sanofi60 enrolled30 locationsNCT07007962